STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Companies Large-Cap

Nike Shows Early Signs of Recovery as Wholesale Strength Offsets Direct Weakness

byLuca Blaumann
December 19, 2025
in Large-Cap, Retail, Textiles, Apparel & Luxury Goods
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Tariffs and digital softness weigh on margins, but leadership signals confidence in long-term turnaround

Nike (NKE) reported mixed results for its fiscal second quarter ended November 30, 2025, as the world’s largest athletic apparel company continues what management describes as the “middle innings” of a broader comeback effort. Revenue rose modestly, driven by strong wholesale performance, while profitability came under pressure from higher tariffs and ongoing shifts in the company’s direct-to-consumer strategy.

Total second-quarter revenue reached $12.4 billion, up 1% on a reported basis and flat on a currency-neutral basis. Growth was led by Nike’s wholesale business, where revenue climbed 8% to $7.5 billion, reflecting improving relationships with retail partners, particularly in North America. In contrast, Nike Direct revenue fell 8% to $4.6 billion, as digital sales declined sharply and traffic at Nike-owned stores softened.

Chief Executive Officer Elliott Hill acknowledged the uneven performance but emphasized progress in key strategic areas. He said Nike is focused on executing its “Win Now” priorities, including realigning teams, strengthening partnerships, rebalancing its product portfolio, and investing in athlete-centered innovation. Hill noted that while the recovery is still underway, the company is beginning to find its rhythm in what he described as a “new sport offense.”

Margin pressure remained a central challenge during the quarter. Gross margin fell 300 basis points to 40.6%, primarily due to higher tariffs in North America. Selling and administrative expenses increased slightly to $4.0 billion, while demand creation spending jumped 13% to $1.3 billion as Nike increased investment in brand and sports marketing. Operating overhead costs declined 4%, reflecting lower wage-related and administrative expenses.

Net income declined 32% to $0.8 billion, and diluted earnings per share fell to $0.53, also down 32% from the prior year. Chief Financial Officer Matthew Friend said the company is making necessary portfolio shifts to support a full recovery, even as near-term earnings remain under pressure.

Regionally, Nike Brand revenue grew in North America but was partially offset by declines in Greater China and Asia Pacific and Latin America. Converse continued to struggle, with revenue dropping 30% amid broad-based weakness across markets.

On the balance sheet, inventories declined 3% to $7.7 billion, reflecting lower unit levels, while cash and short-term investments fell to $8.3 billion due to dividends, debt repayment, share repurchases, and capital spending.

Despite the challenges, management reiterated confidence that the current actions will position Nike for renewed growth and improved profitability over the long term.

You might like this article:Rivian Bets on Vertical Integration to Power Its Autonomous Future

Tags: BreakingGrowthMoversNewsNKEStock Market
Previous Post

Rivian Bets on Vertical Integration to Power Its Autonomous Future

Next Post

CoreWeave Positioned for a Strong Rally—Could Break $100 by Early 2026

Related Posts

opthalmology

UnitedHealth’s Road to $500: Why the Healthcare Giant Could Rally Over the Next 12–14 Months

byLuca Blaumann
January 7, 2026
0

From turnaround strategies to long-term growth drivers, UNH may be poised for a powerful rebound as market sentiment shifts UnitedHealth...

Alumis Breaks Out With Promising Psoriasis Data

byLiliana Vida
January 6, 2026
0

Envudeucitinib positions the biotech for a high-stakes TYK2 showdown heading into 2026 Biotech stock Alumis (ALMS) surged more than 110%...

mining

Lithium’s Comeback: Why Albemarle Could Be Poised for a Strong 2026

byLuca Blaumann
January 6, 2026
0

Rising energy storage demand and tightening supply signal a potential cyclical upturn for lithium markets Lithium prices are showing renewed...

Next Post
investing

CoreWeave Positioned for a Strong Rally—Could Break $100 by Early 2026

Latest News

UnitedHealth’s Road to $500: Why the Healthcare Giant Could Rally Over the Next 12–14 Months

Alumis Breaks Out With Promising Psoriasis Data

Lithium’s Comeback: Why Albemarle Could Be Poised for a Strong 2026

Qualcomm Expands PC Ambitions at CES 2026 With Snapdragon X2 Plus

Five Stock Ideas Kicking Off 2026 as Markets Keep Chasing “More”

Based on Your Interest

Bitcoin

Bitcoin Breaks $92,000 as Bullish Momentum Rebuilds in Early 2026

January 5, 2026
investing
Artificial Intelligence

CES 2026: Where AI Gets Physical

January 2, 2026
investing
Artificial Intelligence

Baidu’s AI Ambitions Take a Market Turn

January 2, 2026

Recommended

Biotechnology

Ironwood Pharmaceuticals Lays Out Ambitious 2026 Outlook

January 2, 2026
Distributor

Midday Market Movers: Nike Shines, Corcept Slides, Taiwan Semiconductor Steadies

December 31, 2025
Bitcoin

Bitcoin Ends a Turbulent Year Under Pressure

December 31, 2025
Entertainment

Warner Bros Discovery Poised to Reject Paramount’s $108.4B Bid

December 30, 2025
Artificial Intelligence

AI Boom Poised to Push Semiconductors Past $1 Trillion, Says Bank of America

December 29, 2025
Stoxpo

Follow us on social media:

Highlights

  • UnitedHealth’s Road to $500: Why the Healthcare Giant Could Rally Over the Next 12–14 Months
  • Alumis Breaks Out With Promising Psoriasis Data
  • Lithium’s Comeback: Why Albemarle Could Be Poised for a Strong 2026
  • Qualcomm Expands PC Ambitions at CES 2026 With Snapdragon X2 Plus
  • Five Stock Ideas Kicking Off 2026 as Markets Keep Chasing “More”

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

opthalmology

UnitedHealth’s Road to $500: Why the Healthcare Giant Could Rally Over the Next 12–14 Months

January 7, 2026

Alumis Breaks Out With Promising Psoriasis Data

January 6, 2026
mining

Lithium’s Comeback: Why Albemarle Could Be Poised for a Strong 2026

January 6, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.